Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Study to Evaluate Oral Rotavirus Vaccine 116E Live Attenuated in Healthy Infants 8 to 20 Weeks Old

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Access to telephone at home or in the immediate neighborhood.~2. Healthy male and female non-malnourished (weight for length not ≤ -3 SD of WHO child growth standards) infants aged 6 weeks (till 6 weeks + 2 days).~3. Parent's permission to participate in the study is available.~4. No plans to travel over the next 4 months~Exclusion Criteria:~1. Gestational age \<37 weeks.~2. Any major physical congenital malformation.~3. Living in a household or has contact with an individual who is immunosuppressed.~4. Hospitalized once or more for the following illnesses since birth: heart disease, pneumonia, sepsis, meningitis, unconsciousness.~5. Is required to take daily medications other than vitamins or herbal tonics.~6. Evidence of cardiovascular disease as indicated by any of the following:~   * Central cyanosis~  * Cyanotic or apnoeic spells~  * Features of congestive heart failure~  * Significant heart murmur detected on physical examination~7. Evidence of gastrointestinal disease indicated by following:~   * Diarrhea in the previous 7 days~  * Blood in the stools any time since birth~8. Evidence of neurological disease, as indicated by:~   * History of seizures any time since birth~  * History of unconsciousness~  * Focal deficit on physical examination~9. Evidence of liver or other reticuloendothelial disease, as indicated by any of the following:~   * Positive serology for hepatitis B surface antigen~  * Positive serology for hepatitis C antibody~  * SGOT or SGPT more than 1.25 times upper limit of normal (Upper limit normal SGOT 80 IU/L, SGPT 40 IU/L)~  * Alkaline phosphatase more than 1.25 times upper limit of normal (Upper limit of normal -470 IU/L)~  * Hepatomegaly (liver palpable 3 cm below costal margin), splenomegaly (palpable spleen), jaundice, or lymphadenopathy on physical examination~  * Serum bilirubin 1.25 times the upper limit of normal for age (Upper limit of normal 1.0 mg/dL).~10. Evidence of hematologic, rheumatologic, or immunologic disease, as indicated by any of the following:~    * Total leukocyte count \<3500 or \>15,000/mm3~   * Hemoglobin \<9 g/dL or \>17g/dL~   * Platelet count \<100,000/mm3~   * Any episode of sepsis, pneumonia or meningitis requiring hospitalization since birth.~11. Evidence of renal disease as indicated by any of the following:~    * Creatinine \>0.5 mg/dL~   * Hematuria (≥5 RBC/hpf)~   * Proteinuria (≥1+ per day)

- Gender: ALL
- Minimum Age: 8 Weeks
- Maximum Age: 20 Weeks
- Healthy Volunteers: t

Study Arms:
- rotavirus vaccine 116E 1 X 10(4) (Type: EXPERIMENTAL): vaccine dose of 1 X 10(4) focus-forming units (ffu) in three doses starting at 6 weeks : 4 weeks apart each dose
- rotavirus vaccine 116E 1 X 10(5) (Type: EXPERIMENTAL): vaccine dose of 1 X 10(5) focus-forming units (ffu) in three doses starting at 6 weeks : 4 weeks apart each dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete